Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder

European Journal of Surgical Oncology

Volumn 40, Issue 1, 2014, Pages 121-127

  Xylinas, E ^a,b,c   Robinson, B D ^a   Kluth, L A ^a,d   Volkmer, B G ^e   Hautmann, R ^f   Kufer R ^g   Zerbib, M ^c   Kwon, E ^h   Thompson, R H ^h   Boorjian, S A ^h   Shariat, S F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c Institut Cochin   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Hospital Kassel   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g Hospital Am Eichert   (Germany)

^h MAYO CLINIC   (United States)

Author keywords

Bladder cancer; Immunohistochemistry; Outcomes; Prognosis; Survival; T cell regulators

Indexed keywords

B7 H3 PROTEIN; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

BLADDER CANCER; IMMUNOHISTOCHEMISTRY; OUTCOMES; PROGNOSIS; SURVIVAL; T-CELL REGULATORS;

ADULT; AGED; ANTIGENS, CD274; B7 ANTIGENS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYSTECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84892544676     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.08.023     Document Type: Article

References (28)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. R.E. Hautmann et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients Eur Urol 61 5 2012 1039 1047
3. S.F. Shariat et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium J Urol 176 6 Pt 1 2006 2414 2422 discussion 2422
4. J.P. Stein et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 3 2001 666 675
5. M. Rink et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes Curr Urol Rep 13 2 2012 122 135
6. Y. Lotan et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Urol Oncol 28 4 2010 441 448
7. S.F. Shariat et al. Statistical consideration for clinical biomarker research in bladder cancer Urol Oncol 28 4 2010 389 400
8. K.L. Knutson, M.L. Disis, and L.G. Salazar CD4 regulatory T cells in human cancer pathogenesis Cancer Immunol Immunother 56 3 2007 271 285
9. D. Mougiakakos et al. Regulatory T cells in cancer Adv Cancer Res 107 2010 57 117
10. H. Nishikawa, and S. Sakaguchi Regulatory T cells in tumor immunity Int J Cancer 127 4 2010 759 767
11. A. Girardin et al. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients Int J Cancer 2012
12. H. Dong et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 8 2002 793 800
13. X. Zang et al. B7x: a widely expressed B7 family member that inhibits T cell activation Proc Natl Acad Sci U S A 100 18 2003 10388 10392
14. R.H. Thompson et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 13 6 2007 1757 1761
15. R.H. Thompson et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 49 2004 17174 17179
16. R.H. Thompson et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 7 2006 3381 3385
17. S.A. Boorjian et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival Clin Cancer Res 14 15 2008 4800 4808
18. A. Stenzl et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 6 2011 1009 1018
19. G. Novara et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients J Urol 183 6 2010 2165 2170
20. M. Rink et al. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy Urol Oncol 2012
21. M. Rink et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma Eur Urol 61 4 2012 854 855
22. P.I. Karakiewicz et al. Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 6 2006 1254 1260 discussion 1261-2
23. S.F. Shariat et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder Urology 57 1 2001 60 65
24. S.F. Shariat et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness Mod Pathol 20 4 2007 445 459
25. S.F. Shariat et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers J Urol 187 2 2012 457 462
26. W.M. Stadler et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 25 2011 3443 3449
27. S.L. Topalian et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
28. J.R. Brahmer et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465